BLTE

About Belite Bio, Inc American Depositary Shares (BLTE) Stock

Belite Bio, Inc American Depositary Shares (BLTE) closed the 2026-09-18 session at $170.96, up 0.36% versus the previous close (+0.61). The stock opened at $168.92 and traded between $168.92 and $172.22 during that session. Session trading volume was 94K shares. The volume-weighted average price (VWAP) is $170.70.

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Belite Bio, Inc American Depositary Shares has a market capitalization of $6.88 billion. BLTE is listed on the XNAS exchange. The company employs approximately 41 people. The recorded listing date is 2022-04-29.

On this page you can find market BLTE stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors.